VINCU

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing novel therapeutic solutions for cancer patients in the United States, aiming to address critical unmet medical needs. The company's leading investigational compound, VIP152, is a cyclin-dependent kinase-9 (CDK9) inhibitor specifically formulated to treat individuals diagnosed with advanced forms of cancer. Its early-stage development pipeline additionally features several promising candidates: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate designed to target solid tumors; and VIP943 and VIP924, both of which are being explored for their potential in combating hematologic malignancies. Vincerx Pharma, Inc. was established in 2019 and operates from its corporate headquarters situated in Palo Alto, California.